Frontier Research in Psychotropic Biology

Advancing the scientific understanding of psychoactive substances, neurochemistry, and their therapeutic applications through interdisciplinary research and innovation.

Explore Our Research Collaborate With Us

About Our Institute

Established in 2014, the Institute of Psychotropic Biology is a world-leading research institution dedicated to the study of psychoactive compounds and their effects on the brain, behavior, and consciousness.

Institute Laboratory

Pioneering Neurochemical Research Since 2014

Our institute brings together neuroscientists, pharmacologists, chemists, and psychologists to explore the complex interactions between psychoactive substances and the human brain. We focus on both fundamental science and translational applications.

With state-of-the-art facilities and a multidisciplinary approach, we aim to unlock the therapeutic potential of psychotropic compounds while advancing our understanding of consciousness, perception, and mental health disorders.

Advanced Laboratories

Cutting-edge facilities for neurochemical analysis and behavioral studies.

Interdisciplinary Teams

Collaborative research across neuroscience, chemistry, and psychology.

PhD Programs

Training the next generation of psychotropic biology researchers.

Global Collaborations

Partnerships with leading institutions worldwide.

12 Research Divisions
150+ Scientific Staff
850+ Publications
42 Countries Represented

Research Areas

Our institute focuses on several key research domains at the intersection of neuroscience, pharmacology, and consciousness studies.

Neurochemistry Research

Neurochemical Mechanisms

Investigating how psychoactive compounds interact with neurotransmitter systems, receptors, and neural pathways to alter brain function and consciousness.

Learn More →
Therapeutic Applications

Therapeutic Applications

Developing novel treatments for psychiatric disorders using psychedelic-assisted therapy, ketamine for depression, and other psychotropic interventions.

Learn More →
Consciousness Studies

Consciousness Studies

Exploring altered states of consciousness induced by psychoactive substances to understand the neural correlates of subjective experience.

Learn More →
Drug Development

Psychotropic Drug Development

Designing and testing new psychoactive compounds with improved therapeutic profiles and reduced side effects.

Learn More →
Behavioral Pharmacology

Behavioral Pharmacology

Studying the effects of psychoactive substances on behavior, cognition, emotion, and social interactions in animal models and humans.

Learn More →
Neuroimaging

Neuroimaging & Biomarkers

Using advanced imaging techniques to visualize brain activity under the influence of psychoactive compounds and identify treatment biomarkers.

Learn More →

Recent Publications

Our researchers regularly publish findings in top scientific journals, contributing to the global knowledge base in psychotropic biology.

15 June 2026

Serotonergic Modulation of Default Mode Network Connectivity in Psychedelic States

A comprehensive fMRI study investigating how psilocybin alters functional connectivity in the human brain's default mode network.

Dr. Elena Rodriguez Nature Neuroscience
02 May 2026

Novel Ketamine Analogs with Reduced Dissociative Effects: A Structure-Activity Relationship Study

Development of new ketamine derivatives that maintain antidepressant efficacy while minimizing dissociative side effects.

Dr. Marcus Chen Journal of Medicinal Chemistry
18 April 2026

MDMA-Assisted Psychotherapy for Treatment-Resistant PTSD: 5-Year Follow-Up Results

Long-term outcomes from a clinical trial demonstrating sustained remission of PTSD symptoms following MDMA-assisted therapy.

Dr. Sarah Johnson The Lancet Psychiatry
View All Publications

Our Leadership Team

Meet the dedicated scientists and researchers who guide our institute's mission and research direction.

Dr. Evelyn Reed

Dr. Evelyn Reed

Director & Chief Neuroscientist

PhD in Neuropharmacology, 20+ years researching psychedelic compounds and consciousness.

Dr. Marcus Chen

Dr. Marcus Chen

Head of Pharmacology

PhD in Medicinal Chemistry, specializing in psychotropic drug design and development.

Dr. Sarah Johnson

Dr. Sarah Johnson

Clinical Research Director

MD, PhD in Psychiatry, leading clinical trials of psychedelic-assisted therapies.

Dr. Kenji Tanaka

Dr. Kenji Tanaka

Head of Neuroimaging

PhD in Cognitive Neuroscience, expert in fMRI and EEG studies of altered states.

Upcoming Events

Join us for conferences, seminars, and workshops on the latest developments in psychotropic biology research.

October
12-14
2026

International Conference on Psychedelic Research

Annual gathering of leading researchers, clinicians, and policymakers to discuss advances in psychedelic science and therapy.

San Francisco, CA
November
05
2026

Neurochemistry of Consciousness Seminar

Special seminar exploring the neurochemical basis of conscious experience and altered states.

Virtual Event
December
08-10
2026

Workshop: Advanced fMRI for Psychedelic Research

Hands-on training in neuroimaging techniques for studying brain activity under psychoactive substances.

Institute Campus
January
20-22
2027

Psychotropic Drug Development Symposium

Bringing together medicinal chemists, pharmacologists, and clinicians to discuss next-generation therapeutics.

Boston, MA

Contact Us

Interested in collaboration, research opportunities, or learning more about our work? Get in touch with our team.

Get In Touch

We welcome inquiries from researchers, students, journalists, and potential collaborators. Our team is available to discuss research partnerships, media requests, and educational opportunities.

Visit Our Campus

Research Park Complex, Building 12
Science District, Metro City 10175

Call Us

+1 (555) 123-4567
Monday - Friday, 9am - 5pm EST

Our Partners

We collaborate with leading academic institutions, research organizations, and industry partners worldwide.